Lyra Therapeutics, Inc.
LYRA
$0.73
-$0.01-1.22%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -96.65% | -87.18% | -69.40% | -65.60% | 43.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -96.65% | -87.18% | -69.40% | -65.60% | 43.15% |
| Cost of Revenue | 63.86% | -31.43% | -61.47% | -73.26% | -393.85% |
| Gross Profit | -64.05% | 29.53% | 61.10% | 73.49% | 399.12% |
| SG&A Expenses | -29.70% | -43.12% | -31.87% | -43.92% | -17.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.65% | -36.10% | -53.21% | -66.17% | -39.99% |
| Operating Income | 29.23% | 35.07% | 52.66% | 66.18% | 40.73% |
| Income Before Tax | 36.67% | 49.60% | 84.55% | 61.93% | 27.52% |
| Income Tax Expenses | -66.67% | -57.14% | -83.33% | -71.43% | -64.71% |
| Earnings from Continuing Operations | 36.69% | 49.60% | 84.55% | 61.93% | 27.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.69% | 49.60% | 84.55% | 61.93% | 27.56% |
| EBIT | 29.23% | 35.07% | 52.66% | 66.18% | 40.73% |
| EBITDA | 29.16% | 35.89% | 53.00% | 66.53% | 41.34% |
| EPS Basic | 53.33% | 62.68% | 85.00% | 62.94% | 31.96% |
| Normalized Basic EPS | 46.74% | 50.95% | 54.08% | 66.78% | 42.11% |
| EPS Diluted | 53.33% | 62.68% | 85.00% | 62.94% | 31.96% |
| Normalized Diluted EPS | 46.74% | 50.95% | 54.08% | 66.78% | 42.11% |
| Average Basic Shares Outstanding | 35.65% | 35.04% | 3.01% | 2.73% | 6.46% |
| Average Diluted Shares Outstanding | 35.65% | 35.04% | 3.01% | 2.73% | 6.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |